

1 Markers of systemic iron status show sex-specific differences in peripheral artery 2 disease: a cross-sectional analysis of HEIST-DiC and NHANES participants

3

4

5 Anand Ruban Agarvas¹, Stefan Kopf^{2,3}, Paul Thalmann⁴, José Manuel Fernández-
6 Real⁵, Peter Nawroth^{2,3}, *Martina U. Muckenthaler^{1,6,7,8}

7

8 Affiliations

9 ¹Center For Translational Biomedical Iron Research, Department of Pediatric Hematology,
10 Oncology Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg,
11 Germany.

12 ²Clinic for Endocrinology, Diabetology, Metabolic Diseases and Clinical Chemistry (Internal
13 Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.

14 ³German Center of Diabetes Research (DZD), Neuherberg, Germany.

15 ⁴Institute of Medical Biometry, University Hospital Heidelberg, Heidelberg, Germany.

16 ⁵Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de
17 Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona
18 17007, Spain.

19 ⁶Molecular Medicine Partnership Unit, Heidelberg, Germany.

20 ⁷Translational Lung Research Center Heidelberg (TLRC), German Center for Lung
21 Research (DZL), University of Heidelberg, Heidelberg, Germany.

22 ⁸German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim,
23 Germany.

24

25 *Corresponding author

26

27

28 Address for correspondence

29 Department of Pediatric Hematology, Oncology and Immunology, University of Heidelberg,
30 Heidelberg, Germany.

31 Tel.: +496221566923; Fax: +496221564580. E-mail: [martina.muckenthaler@med.uni-](mailto:martina.muckenthaler@med.uni-heidelberg.de)
32 [heidelberg.de](mailto:martina.muckenthaler@med.uni-heidelberg.de) (M.U. Muckenthaler).

33 Abstract

34 Background

35 Iron has been proposed as a risk factor for atherosclerosis but the data are controversial.
36 We previously showed that non-transferrin-bound iron (a fraction of iron appearing in iron
37 overload) contributes to atherosclerosis. Here, we investigated whether iron within
38 physiological limits influenced atherosclerosis by studying its association with vascular
39 dysfunction and peripheral arterial disease (PAD). Further, we evaluated if this relationship
40 was influenced by comorbidities.
41

42 Methods

43 We studied the association between iron biomarkers in blood and markers for vascular
44 adhesion and PAD in 368 individuals registered in the Heidelberg Study on Diabetes and
45 Complications (HEIST-DiC). Our observations were validated by analyzing the association
46 between iron biomarkers and PAD in the National Health and Nutrition Examination Survey
47 (NHANES 1999-2004) data.
48

49 Results

50 In both HEIST-DiC and NHANES cohorts, plasma ferritin levels are positively associated
51 with PAD in females and not in males. We further identified negative associations between
52 TIBC and plasma iron levels with PAD among females. These relationships were
53 independent of the presence of other comorbidities including hypertension, insulin
54 resistance, prediabetes, and diabetes.
55

56 Conclusion

57 We demonstrate a sex-specific alteration of markers of systemic iron availability in
58 individuals with clinically apparent PAD implying that mechanisms of disease development
59 may differ between males and females. Elevated ferritin levels and hypoferrremia in females
60 are indicative of an underlying inflammation that may affect the pathogenesis of PAD. The
61 observed lack of a positive association of PAD with serum iron levels suggest that
62 “physiological” iron concentrations are safe for vascular health.
63

64 Keywords

65 Iron, Vascular Diseases, Arterial Occlusive Diseases, Atherosclerosis, Peripheral Arterial
66 Disease

67 Introduction

68 Peripheral arterial disease (PAD) is a common atherosclerotic vascular disorder of the
69 arteries of the lower limbs and affects millions of individuals worldwide^{1,2}. Unrecognized and
70 untreated PAD reduces blood flow to the lower extremities resulting in leg pain, impaired
71 mobility, and amputation. Moreover, it is associated with an increased risk of cardiovascular
72 morbidity and mortality³. Compared to cardiovascular and cerebrovascular disease, PAD is
73 less well studied, and our understanding of the disease process is still poor. Among the
74 known risk factors of PAD include old age, smoking, and comorbidities such as diabetes and
75 hypertension¹. A recent genome-wide association study⁴ identified genetic loci that are
76 unique to PAD, in addition to those shared between the different atherosclerotic disorders
77 (coronary, cerebral, and peripheral) suggesting that additional mechanisms may contribute
78 to the pathophysiology of PAD.

79
80 Iron is an essential micronutrient and its homeostasis is controlled by regulatory systems
81 that maintain its absorption, transport, and storage⁵. If iron accumulates in excess, it
82 contributes to the generation of reactive oxygen species. Iron is, therefore, discussed as a
83 risk factor for the development of atherosclerosis and cardiovascular disease⁶. We
84 previously analysed mouse models and humans with iron overload disorder,
85 hemochromatosis, and found that excess iron played a multifaceted role in atherosclerosis
86 depending on the compartment where it is localized⁷. Under physiological conditions, iron is
87 bound to transferrin in the plasma, and is transported to those cells that require iron. Iron
88 occupies only one-third of transferrin's binding sites, therefore, free iron can be sequestered
89 in the circulation. However, in pathological states associated with iron overload, most binding
90 sites on transferrin are saturated resulting in the appearance of 'non-transferrin-bound iron
91 (NTBI)'. We found that NTBI in circulation contributes to atherosclerosis by oxidising low-
92 density lipoproteins (LDL) and inducing vascular dysfunction⁷. In addition, iron deposition in
93 the vasculature of hemochromatotic mice was associated with enhanced atherosclerosis⁷.
94 An interesting open question is whether iron levels within physiological limits influence
95 atherogenesis. The available data is controversial.

96
97 The relationship between iron and atherosclerosis has been commonly studied by analyzing
98 the association of one or more iron biomarkers [e.g. plasma iron, ferritin, transferrin,
99 transferrin saturation (TSAT)] with atherosclerosis markers (e.g. coronary artery calcium or
100 carotid intima-media thickness)⁸⁻¹⁴. On the other hand, studies have also been performed
101 that consider blood donation as an iron-depletion strategy and evaluated atherosclerosis risk
102 in blood donors¹⁵⁻¹⁹. More recently, Gill *et al.* used a Mendelian randomization approach to

evaluate the risk of venous thromboembolism and carotid atherosclerosis with the genetically determined iron status¹⁴.

The relationship between iron and PAD is less well-studied. Menke *et al.* showed that ferritin and TSAT are positively associated with PAD in the National Health and Nutrition Examination Survey 1999-2002 (NHANES), especially among participants with elevated cholesterol²⁰. Among individuals on hemodialysis, one study found that PAD was associated with anemia and low iron levels²¹ while the other found a positive association with ferritin levels²². Results of a randomized controlled trial suggested that among participants with established PAD, the iron reduction did not improve the clinical outcomes or mortality²³. Several open questions remain: Are there differences in how iron parameters influence atherosclerosis at different sites? Do iron biomarkers correlate with the severity of PAD? If so, how? How are these relationships influenced by sex or the presence of prediabetes or diabetes?

Here we analyzed iron biomarkers within physiological limits for association with markers for vascular function and PAD in a cohort of individuals with diabetes and prediabetes enrolled in the Heidelberg Study on Diabetes and Complications (HEIST-DiC). We validated our observations by analyzing the NHANES 1999-2004 data.

Methods

Participants

HEIST-DiC study

We retrospectively analysed the data from 368 individuals enrolled in the HEIST-DiC study (Clinical trials.gov NCT03022721). The selection criteria for participants have been described previously²⁴; in addition, we excluded those with values of serum iron biomarkers suggestive of likely hemochromatosis²⁵. For all participants, a detailed medical history was obtained. The ankle-brachial index (ABI) was measured using noninvasive blood pressure measurements of arms and ankles (ABI System 1000; Boso d.o.o.). Blood samples were obtained in the fasting state and all baseline parameters were analyzed under standardized conditions in the central laboratory of the University Hospital of Heidelberg. Serum samples were stored at -80°C until further analysis. We used iron, ferritin, and TSAT were used as biomarkers of systemic iron status and serum intercellular adhesion molecule-1 (ICAM1) and vascular-cell adhesion molecule-1 (VCAM1) were used as markers of vascular dysfunction. We measured ICAM1 (#171B6009M) and VCAM1 (#171B6022M) using multiplex magnetic bead-array-based technology on a BioPlex200 system (Bio-Rad) according to the manufacturer's instructions. All participants provided written informed consent and the ethics

committees of the University of Heidelberg approved this study (Decision No. 204/2004, 400/2010, and S-383/2016) according to the Declaration of Helsinki.

NHANES

NHANES is designed to assess the health and nutritional status of adults and children in the United States. The survey includes both an interview component, in which participants are asked questions about their health and lifestyle, and a physical examination component, in which various measurements and samples are collected. We obtained data from 15969 participants over 40 years in 3 consecutive cycles of NHANES (1999-2004) for whom ABI was measured. We applied the following exclusion criteria: not even one ABI measurement available, likely hemochromatosis²⁵, anemia (hemoglobin <10g/L), on current hormonal medications or iron supplements, cancer, donated blood in the last 1 month, with features of kidney disease (on dialysis or severe albuminuria), pregnant or breastfeeding in the last year, high risk of liver fibrosis, concurrent inflammation [C-Reactive Protein (CRP) >3μg/L] and with a feature of familial hyperlipidemia [LDL-Cholesterol (LDLc) >4.9mM]. This resulted in a final sample number of 9336 participants. We obtained data from the following iron biomarkers from NHANES: iron, ferritin, total iron binding capacity (TIBC), and TSAT.

Among the demographic variables, age (in years) and body mass index (BMI) were obtained and used as is from NHANES. Smoking and alcohol were categorized according to a previous study²⁶. We categorized diabetes based on self-reported history, current use of insulin or oral hypoglycemic agents, fasting plasma glucose (FPG) ≥7.0 mM, or glycated hemoglobin (HbA1c) ≥6.5%. Prediabetes was defined among those with an absent self-reported history of diabetes and one of the following: FPG 5.6-6.9 mM or HbA1c 5.7-6.4%. We categorized hypertension based on self-reported history or current use of anti-hypertensive agents or systolic blood pressure >130 mmHg or diastolic blood pressure >80 mmHg. The presence of nonalcoholic fatty liver disease (NAFLD) was categorized by calculating FIB-4 score²⁷. Assays for the analytes in NHANES were performed under strict laboratory protocols (for more details on data fields and procedure manuals, see Supplementary Table 2). As an index of insulin resistance, we calculated HOMA2-IR using C-peptide values instead of insulin²⁸.

Categorization as PAD

In both cohorts, ABI values were measured on both the right and left limbs. We categorized PAD when the ABI value on one of the sides was <0.9 or >1.4 as per recommendations²⁹.

Statistical analysis

For the analysis of participants in both cohorts, the following aspects were similar: we modelled the probability of PAD's presence with one of the iron biomarkers (iron, ferritin, or TSAT) by logistic regression using a nested approach. Since iron metabolism shows sex-specific differences, we conducted a sex-stratified analysis. In general, we included variables that are known to affect iron homeostasis or the risk of PAD as covariates. Further, all continuous variables were mean-centered for the analysis, and variables were included in the models only when their missing data was <10%.

Some study-specific aspects of the analysis are described below. For the HEIST-DiC study, we built 3 different regression models that analysed the association between iron biomarkers and PAD or markers of vascular dysfunction (ICAM1, VCAM1). Model 1 was univariate. Model 2 was built on model 1 by adjusting for demographic variables: sex (males as reference), presence of diabetes, and hypertension (absence of disease as reference). Model 3 was built on Model 2 by including additional covariates [high sensitivity CRP (hsCRP), LDLc, HbA1c, and urine albumin creatinine ratio (ACR); all continuous]. As subgroup analysis in the HEIST-DiC cohort, we conducted univariate regression for iron parameters only in individuals with diabetes; we did not conduct a subgroup analysis for prediabetes since the number of patients with PAD in this group was small (2/23).

For the NHANES data, only the association between iron biomarkers and PAD was analyzed. Model 1 represents the univariate analysis, while models 2-4 are multivariate. Model 2 was built on model 1 by adjusting for demographic variables (age, BMI, smoking (non-smokers as reference), and ethnicity (non-Hispanic whites as the reference). Model 3 was built on model 2 by incorporating the following covariates (as categorical: the presence of diabetes, and hypertension (absence of disease as reference), FIB4 score [<1.2 as reference]; as continuous: CRP, ACR. Model 4 was built on model 3 by including HOMA2-IR, LDLc, use of antihyperlipidemic and antiplatelet agents (the former two variables as continuous and the latter two as categorical). For the NHANES dataset, we also conducted a sensitivity analysis by conducting the analyses on the whole cohort without the exclusion of data. In addition, sample weights were included all the analyses.

A p-value<0.05 was considered statistically significant. All statistical analyses and visualizations were performed using R Statistical Software (v4.2.2³⁰). Reporting of the study is as per The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines³¹. We have also developed a data exploration tool for readers to explore the datasets and interactively create their visualizations from the paper (https://anandr.shinyapps.io/NHANES_HEISTDiC/) using Quarto³² and Shiny³³.

Results

HEIST-DiC study

The HEIST-DiC is a prospective, observational study designed to analyze the development of complications in individuals with diabetes and prediabetes. We investigated the relationship between systemic iron biomarkers and PAD in the baseline data and the participant characteristics are shown in Table 1. The overall prevalence of PAD was 6.6% with a higher proportion among males (17/192) than females (6/165). Among both sexes, the participants with PAD were older and a majority of them also had associated diabetes and hypertension; the proportion of individuals with prediabetes and PAD was small (Table 1). Vascular adhesion markers such as ICAM1 and VCAM1 were significantly higher only among the males with PAD (Table 1). Among the iron biomarkers, ferritin was elevated among females with PAD while iron, transferrin, and TSAT were not significantly different. Of note, significant differences between iron parameters and PAD were not noted in males.

In the regression analyses, ferritin was associated with an increased probability of PAD in females but not males (Figure 1). This positive association was significant in models 1 and 2 (Model 1: OR 3.23, 95% CI 1.23-8.7, P=0.013, Model 2: OR 2.87, 95% CI 0.96-9.18, P=0.06) however, an increased risk was also evident in the Model 3 (OR 1.86, 95% CI 0.38-8.1, P=0.4). The positive association of ferritin with PAD persisted in models adjusted for the comorbidities diabetes and hypertension (Model 2 and Model 3); further, ferritin also showed a tendency for a positive association in the diabetes subgroup (OR 2.44, 95% CI 0.8-7.14, P=0.09). On the other hand, iron and TSAT did not show a significant association with PAD in either sex (Figure 1). In contrast to our previous observations in individuals with hemochromatosis⁷, markers of vascular dysfunction such as ICAM1 and VCAM1 were not significantly associated with iron parameters within physiological ranges (iron, ferritin, or TSAT) in both sexes (Figures 2-3).

NHANES

This part of the study builds upon a previous analysis of the NHANES 1999-2002 cycles by Menke *et al.*²⁰ by including data from the NHANES 2003-2004 cycle. The baseline characteristics of the NHANES 1999-2004 participants included in the study are shown in Table 2. Overall, the prevalence of PAD in the population was 6.25% with a significantly higher prevalence among females (males: 4.96%, females: 7.9%; p=0.001). Among individuals with PAD, we observed differences in ethnicity, sex, presence of diabetes, smoking, alcohol status, physical activity, and use of antihyperlipidemic and antiplatelet medications (Table 2). The prevalence of PAD increased with older age (median: 69 for

males, $P < 0.001$; 71 for females, $P < 0.001$) with a higher percentage from the non-Hispanic white ethnicity (84% for males, $P = 0.003$; 78% for females, $P = 0.005$). BMI was significantly higher among females with PAD while it was not different for males (median: 28 for males, $P = 0.8$; 29 for females, $P = 0.014$). The proportion of alcohol drinkers was comparable for both sexes and was not statistically different (5.2% for males, $P = 0.6$; 6% for females, $P > 0.9$).

Among both sexes, the proportion of PAD participants with prediabetes (2.4% for males; 2.7% for females) or diabetes (2.3% for males; 3.0% for females) were comparable. The overall prevalence of hypertension was higher among those with PAD (9.9% of males, $p = 0.003$; and 11.8% of females, $p = 0.6$). Smoking status was different among the sexes in the PAD group: among males, the proportion of former and current smokers was significantly higher (Non-smokers 1.7%, Former smokers 4.2%, Current smokers 2.3%; $P < 0.001$) while the distribution was not different among females (Non-smokers 5.4%, Former smokers 3.1%, Current smokers 1.8%; $P = 0.2$). As expected, lower physical activity was also associated with PAD in both sexes (50% of males and 57% of females). Among both sexes, the PAD subgroup also had a higher FIB4 score indicating a greater degree of liver fibrosis (Males: 1.35, $P < 0.001$; Females: 1.14 $P < 0.001$).

Among the iron biomarkers, serum iron (Median 80, IQR 64-108 $\mu\text{g/dL}$; $P < 0.001$) and transferrin saturation (Median 24, IQR 17-30; $P = 0.021$) were lower in males with PAD while females with PAD showed higher ferritin (Median 87, IQR 56-252 ng/mL ; $P < 0.001$) and lower TIBC (Median 60, IQR 54-68; $P < 0.001$). Marginal differences were also observed in some laboratory parameters within both sexes with PAD (e.g. albumin, AST, urea, creatinine, C-reactive protein, and albumin-creatinine ratio; Table 2).

Consistent with our observations in the HEIST-DiC cohort, serum ferritin levels showed a positive association with PAD only in females (Figure 4). This positive association was strongest in Model 4, the most complex regression model we built (OR 3.6, 95% CI 1.25-10.6, $P = 0.018$). Interestingly, TIBC analysis showed a significant negative association with PAD only among females (OR 0.71, 95% CI 0.58-0.88, $P = 0.002$; Model 2: OR 0.63, 95% CI 0.5-0.79, $P < 0.001$; Model 3: OR 0.56, 95% CI 0.41-0.75, $P < 0.001$; Model 4: OR 0.29, 95% CI 0.12-0.7, $P = 0.006$; Figure 4). By contrast, none of the associations for ferritin and TIBC were significant for males. On the other hand, serum iron levels (Figure 4), were negatively associated with PAD in both females (Model 1: OR 0.75, 95% CI 0.61-0.92, $P = 0.005$; Model 2: OR 0.77, 95% CI 0.61-0.98, $P = 0.034$; Figure 4) and males (Model 1: OR 0.79, 95% CI 0.62-1, $P = 0.046$). For TSAT, a positive association for females was observed in Model 4 (OR 2.87, 95% CI 1.15-6.92, $P = 0.023$) while a negative association was noted for males

(Model 1: OR 0.75, 95% CI 0.61-0.93, P=0.008; Model 2: OR 0.8, 95% CI 0.64-0.99, P=0.041; Figure 4).

We next analysed associations of other covariates with PAD from Model 4 (Supplementary Table 1). Of note, BMI had no association with PAD, while smoking showed a positive association among both sexes that was more pronounced in males; interestingly, male former smokers showed a negative association with PAD although, a positive association still remained among females (Supplementary Table 1). Furthermore, the presence of prediabetes was positively associated with PAD among males and negatively among females; on the other hand, the presence of diabetes was negatively associated with PAD in both sexes. HOMA2-IR showed positive associations among both males and females while CRP showed a positive association mainly among females (Supplementary Table 1).

Sensitivity analysis

To test the robustness of the relationships, we conducted a sensitivity analysis on the whole NHANES 1999-2004 cohort without applying any exclusion criteria. Here, we found that ferritin (in Model 1) and TIBC's observations in females (Models 1-3) were robust enough to retain their significant relationships (Supplementary Figure 1).

Discussion

While the majority of studies undertaken so far have focused on the relationship between iron and cardiovascular disease, only a few studies have investigated the role of iron in the development of atherosclerosis: furthermore, the topic of how iron biomarkers correlate with PAD, specifically, is rarely addressed. We, therefore, analyzed the data from two patient cohorts: HEIST-DiC and NHANES. Since iron parameters show important sex-specific differences, we conducted stratified analyses for males and females and additionally analysed if prediabetes or diabetes affected the observed relationships.

There were no significant associations between iron parameters within the physiological range and markers of vascular dysfunction (ICAM1 or VCAM1), despite their elevated levels in males with PAD. However, we observed sex-specific associations of iron biomarkers with PAD, a relationship that was independent of the presence of other comorbidities including hypertension, insulin resistance, prediabetes, and diabetes (Supplementary Table 1). In both, the HEIST-DiC and NHANES patient cohorts, plasma ferritin levels are positively associated with PAD in females and not in males. The positive association for higher serum ferritin among females with PAD reported here strengthens the previous observations on the NHANES 1999-2001 cohort²⁰ and agrees with a previous study on carotid atherosclerosis³⁴.

These findings are also, at least, partially consistent with studies that report ferritin's positive association with carotid/coronary atherosclerosis. These studies do not observe major sex-specific differences^{8,12,13}. On the contrary, the lack of a predictive role for ferritin in males is in contrast to a previous study which reports a "U-shaped" relationship with cardiovascular disease among males³⁵. The sex-specific associations of ferritin identified in the patient cohorts described here also contrast findings in two other large cohort studies: i) a Danish cohort that observed an increased risk of all-cause mortality for ferritin among both males and females³⁶ and ii) a British cohort that observed an increased risk of cardiovascular mortality among males with high ferritin and increased all-cause mortality among females with low ferritin³⁷.

Interestingly, in the NHANES cohort, we further identified negative associations between TIBC with PAD in females but not in males. This relationship between TIBC and PAD was strong and robust, as evident from the sensitivity analysis (Figure 4; Supplementary Figure 1). Our findings thus support two previous studies that have analyzed the relationship between TIBC and atherosclerosis^{12,38}. Further, among both sexes, plasma iron showed a negative association with PAD. The following studies on plasma iron and PAD do show similar negative associations but have not investigated sex-specific differences. For example, serum iron levels were reduced in hemodialysis patients with PAD ($9.9 \pm 3.0 \mu\text{M}$) compared to those without PAD ($11.5 \pm 3.3 \mu\text{M}$; $p=0.004$)²¹. The study by Vega De Céniga *et al.* also observed a higher prevalence of iron deficiency (31.9% with iron $<58 \text{ mcg/dL}$) and anemia (49.5%) among PAD participants³⁹.

In our analyses, the association for TSAT with PAD showed contrasting observations in males and females. While the HEIST-DiC cohort had insignificant associations for TSAT (Figure 3), the NHANES cohort showed a positive association among females in Model 4 while the association was negative among males (Figure 4). Otaki *et al.* reported reduced TSAT levels in PAD in a Japanese patient cohort and also found a correlation between TSAT with the severity of PAD⁴⁰. Similar negative associations with TSAT have also been made in the context of cardiovascular disease in both sexes^{11,12,14,41}. For the interpretation of TSAT, it is also important to consider that it is a calculated measure⁴². While the HEIST-DiC study applied a formula including measured transferrin levels, the NHANES cohort used a formula applying TIBC. Therefore, we are cautious in interpreting the associations of TSAT in our study.

Our data extend on our previous findings, where we observed a striking correlation of NTBI and vascular dysfunction and atherosclerosis.^{7,43} From this current study we conclude that serum iron levels within physiological limits are safe for vascular health. These findings agree with our previous proposed model⁷ that only the labile iron fractions in the circulation (eg., NTBI) in iron-loaded states plays a pathological role. Nevertheless, the associations between iron biomarkers with PAD in females have several important implications. If ferritin were interpreted as an indicator of body iron stores, our study suggests that there is an increased risk of PAD at the upper end of, what is clinically accepted as a “physiological” iron status. This finding would directly contrast our observation on the negative relationship between PAD and iron/TIBC which implies an increased PAD risk in iron-deficient states. This could be interpreted as an “U-shaped” relationship between iron status and cardiovascular disease as noted in two previous studies investigating the NHANES cohort^{41,44,45}. However, ferritin is also an acute phase reactant with increased expression in conditions of inflammation⁴⁶. In inflammatory conditions, hypoferrremia (low iron levels in the plasma) arises from a reduced iron export via ferroportin from macrophages and duodenal enterocytes by hepcidin-controlled⁴⁷ and transcriptional mechanisms^{48,49}. Consequently, iron-exporting cells such as macrophages become iron loaded contributing to elevated ferritin levels⁵⁰. Overall, our findings may also suggest an iron redistribution in response to an underlying inflammation that may render individuals more susceptible to PAD. Although we excluded samples with CRP<3 mg/dL and used CRP as a covariate, the presence of microinflammation in tissues cannot be completely excluded from the available data.

We further need to interpret our findings in the context of The Iron and Atherosclerosis Study (FeAST; www.clinicaltrials.gov, Identifier NCT00032357), a major trial that investigated the benefits of iron reduction on the clinical outcomes in a cohort of individuals with PAD²³. While the initial analysis of the FeAST trial results did not report a favorable outcome following phlebotomy²³, the reanalysis of the results adjusting for the effects of age⁵¹ and smoking⁵² have suggested that iron reduction (with ferritin and TSAT as endpoints) could be of significant benefit for younger individuals and smokers. However, an overwhelming majority of the FeAST trial participants are males (~98%)²³, therefore, sex-specific differences could not be analyzed.

Taken together, our data suggest that iron redistribution to macrophages and reduced systemic iron availability may play a role in PAD. Some of the parameters analyzed are altered in a sex-specific manner implying that mechanisms of PAD development may differ between males and females. The strength of our study lies in the analyses of two independent cohorts, allowing for a generalization of the findings, an increased robustness

of the data, and a reduction of cohort-specific biases. In both cohorts, we observed a similar prevalence of PAD (~6%) associated with well-known risk factors (old age, diabetes, and hypertension). The examination of multiple iron biomarkers, including serum iron, ferritin, TSAT, and TIBC provides a comprehensive analysis of the relationship between iron and clinically apparent PAD. This is also the first study to evaluate the relationship between iron biomarkers and PAD in prediabetes and diabetes.

Limitations include the cross-sectional nature of the study which limits causal inferences and precludes the assessment of temporal relationships. The HEIST-DiC cohort consisted of mainly European individuals with diabetes and prediabetes from a hospital-based study, while NHANES is a survey cohort, representative of the US population, and therefore contains a mix of ethnicities. Further, we were unable to control for all possible confounding factors, such as genetic predisposition, lifestyle, medications, or other comorbidities. The study described here also did not investigate potential mechanisms underlying the observed associations.

Conclusion

Overall, our findings suggest that “physiological” iron concentrations are safe for vascular health. We also find evidence of an association between systemic iron biomarkers and PAD specifically among females. Further studies are necessary to confirm whether the observed associations are indeed causal and to explore the potential mechanisms underlying this relationship. Understanding the role of iron in the development of PAD could lead to the development of new preventive and therapeutic strategies for this condition. Our findings need to be considered explorative to encourage the investigation of potential biological pathways underlying the sex-specific differences in iron’s influence on atherosclerosis.

Ethics statement

The ethics committees of the University of Heidelberg approved this study (Decision No. 204/2004, 400/2010, and S-383/2016) according to the Declaration of Helsinki. All patients entered the study according to the guidelines of the local ethics committees following written informed consent to participate.

Funding

The HEIST-DiC study was funded by the Deutsche Forschungsgemeinschaft (SFB1118). MUM received funding from the DFG (SFB1118) and Translational Lung Research Center

Heidelberg (TLRC), German Center for Lung Research (DZL; Project No. FKZ 82DZL004A1).

Author contributions

Anand Ruban Agarvas: Conceptualization, Methodology, Software, Formal analysis, Investigation, Data curation, Writing- Original draft, Visualization
 Stefan Kopf: Investigation, Resources, Writing - Review & Editing
 Paul Thalmann: Validation, Writing - Review & Editing
 José Manuel Fernández-Real: Methodology, Writing - Review & Editing, Supervision
 Peter Nawroth: Project administration, Funding acquisition, Supervision, Writing - Review & Editing
 Martina U. Muckenthaler: Conceptualization, Methodology, Supervision, Writing - Review & Editing, Project administration, Funding acquisition

Conflict of interest

None to declare

Data and Code Availability Statement

The data from this study can be explored here: https://anandr.shinyapps.io/NHANES_HEISTDiC/. The HEIST-DiC dataset analyzed in the current study is available from the corresponding authors on reasonable request. The NHANES dataset is publicly available. Codes used for data analysis and visualization are accessible here (<https://github.com/griffindoc/pad>)

References

1. Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and Polyvascular Disease. *Circ Res*. 2021;128(12):1818-1832. doi:10.1161/CIRCRESAHA.121.318535
2. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *The Lancet*. 2013;382(9901):1329-1340. doi:10.1016/S0140-6736(13)61249-0
3. Fowkes F, Murray G, Butcher I, Folsom A, Hirsch A, Couper D, DeBacker G, Kornitzer M, Newman A, Sutton-Tyrrell K, Cushman M, Lee A, Price J, D'Agostino R, Murabito J, Norman P, Masaki K, Bouter L, Heine R, Stehouwer C, McDermott M, Stoffers H, Kottner J, Ogren M, Hedblad B, Koenig W, Meisinger C, Cauley J, Franco O, Hunink M, Hofman A, Witteman J, Criqui M, Langer R, Hiatt W, Hamman R, Ankle Brachial Index Collaboration. Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events. *Eur J Prev Cardiol*. 2014;21(3):310-320. doi:10.1177/2047487313516564

- 474 4. VA Million Veteran Program, Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, Lee
475 KM, Shao Q, Huffman JE, Natarajan P, Arya S, Small A, Sun YV, Vujkovic M, Freiberg MS, Wang
476 L, Chen J, Saleheen D, Lee JS, Miller DR, Reaven P, Alba PR, Patterson OV, DuVall SL, Boden WE,
477 Beckman JA, Gaziano JM, Concato J, Rader DJ, Cho K, Chang KM, Wilson PWF, O'Donnell CJ,
478 Kathiresan S, Tsao PS, Damrauer SM. Genome-wide association study of peripheral artery
479 disease in the Million Veteran Program. *Nat Med*. 2019;25(8):1274-1279. doi:10.1038/s41591-
480 019-0492-5
- 481 5. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. *Cell*.
482 2017;168(3):344-361. doi:10.1016/j.cell.2016.12.034
- 483 6. Sullivan Jerome L. IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK. *The Lancet*.
484 1981;317(8233):1293-1294. doi:10.1016/S0140-6736(81)92463-6
- 485 7. Vinchi F, Porto G, Simmelbauer A, Altamura S, Passos ST, Garbowski M, Silva AMN, Spaich S,
486 Seide SE, Sparla R, Hentze MW, Muckenthaler MU. Atherosclerosis is aggravated by iron
487 overload and ameliorated by dietary and pharmacological iron restriction. *Eur Heart J*.
488 Published online March 20, 2019. doi:10.1093/eurheartj/ehz112
- 489 8. Wolff B, Völzke H, Lüdemann J, Robinson D, Vogelgesang D, Staudt A, Kessler C, Dahm JB, John
490 U, Felix SB. Association between high serum ferritin levels and carotid atherosclerosis in the
491 study of health in Pomerania (SHIP). *Stroke*. 2004;35(2):453-457.
492 doi:10.1161/01.STR.0000114875.31599.1C
- 493 9. Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD. Ferritin Is Independently Associated
494 With the Presence of Coronary Artery Calcium in 12 033 Men. *ATVB*. 2012;32(10):2525-2530.
495 doi:10.1161/ATVBAHA.112.253088
- 496 10. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid
497 atherosclerosis: prospective results from the Bruneck study. *Circulation*. 1997;96(10):3300-
498 3307. doi:10.1161/01.cir.96.10.3300
- 499 11. Das De S, Krishna S, Jethwa A. Iron status and its association with coronary heart disease:
500 systematic review and meta-analysis of prospective studies. *Atherosclerosis*. 2015;238(2):296-
501 303. doi:10.1016/j.atherosclerosis.2014.12.018
- 502 12. Guo S, Mao X, Li X, Ouyang H. Association between iron status and incident coronary artery
503 disease: a population based-cohort study. *Sci Rep*. 2022;12(1):17490. doi:10.1038/s41598-022-
504 22275-0
- 505 13. Klip IJT, Voors AA, Swinkels DW, Bakker SJL, Kootstra-Ros JE, Lam CS, Van Der Harst P, Van
506 Veldhuisen DJ, Van Der Meer P. Serum ferritin and risk for new-onset heart failure and
507 cardiovascular events in the community: Serum ferritin and risk for new-onset HF and CV
508 events. *Eur J Heart Fail*. 2017;19(3):348-356. doi:10.1002/ehf.622
- 509 14. Gill D, Brewer CF, Monori G, Trégouët DA, Franceschini N, Giambartolomei C, INVENT
510 Consortium, Tzoulaki I, Dehghan A. Effects of Genetically Determined Iron Status on Risk of
511 Venous Thromboembolism and Carotid Atherosclerotic Disease: A Mendelian Randomization
512 Study. *J Am Heart Assoc*. 2019;8(15):e012994. doi:10.1161/JAHA.119.012994
- 513 15. Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssonen K. Donation of Blood Is Associated
514 with Reduced Risk of Myocardial Infarction: The Kuopio Ischaemic Heart Disease Risk Factor

- Study. *American Journal of Epidemiology*. 1998;148(5):445-451.
doi:10.1093/oxfordjournals.aje.a009669
16. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. *Transfusion*. 2002;42(9):1135-1139.
doi:10.1046/j.1537-2995.2002.00186.x
17. Meyers DG, Strickland D, Maloley PA, Seburg JK, Wilson JE, McManus BF. Possible association of a reduction in cardiovascular events with blood donation. *Heart*. 1997;78(2):188-193.
doi:10.1136/hrt.78.2.188
18. Peffer K, Den Heijer M, Holewijn S, De Graaf J, Swinkels DW, Verbeek ALM, Atsma F. The effect of frequent whole blood donation on ferritin, hepcidin, and subclinical atherosclerosis: Subclinical Atherosclerosis in Blood Donors. *Transfusion*. 2013;53(7):1468-1474.
doi:10.1111/j.1537-2995.2012.03916.x
19. Riško P, Pláteník J, Buchal R, Potočková J, Kraml PJ. Long-term donors versus non-donor men: Iron metabolism and the atherosclerotic process. *Atherosclerosis*. 2018;272:14-20.
doi:10.1016/j.atherosclerosis.2018.03.009
20. Menke A, Fernández-Real JM, Muntner P, Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. *BMC Cardiovasc Disord*. 2009;9(1):34.
doi:10.1186/1471-2261-9-34
21. Aščerić RR, Dimković NB, Trajković GŽ, Ristić BS, Janković AN, Durić PS, Ilijevski NS. Prevalence, clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a cross-sectional study. *BMC Nephrol*. 2019;20(1):281. doi:10.1186/s12882-019-1468-x
22. Lien CT, Lin KC, Tsai YF, Yu LK, Huang LH, Chen CA. Serum ferritin is associated with progression of peripheral arterial disease in hemodialysis patients. *Clin Exp Nephrol*. 2015;19(5):947-952.
doi:10.1007/s10157-014-1074-y
23. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. Reduction of Iron Stores and Cardiovascular Outcomes in Patients With Peripheral Arterial Disease: A Randomized Controlled Trial. *JAMA*. 2007;297(6):603.
doi:10.1001/jama.297.6.603
24. Altamura S, Kopf S, Schmidt J, Müdder K, da Silva AR, Nawroth P, Muckenthaler MU. Uncoupled iron homeostasis in type 2 diabetes mellitus. *J Mol Med*. 2017;95(12):1387-1398.
doi:10.1007/s00109-017-1596-3
25. Zoller H, Schaefer B, Vanclooster A, Griffiths B, Bardou-Jacquet E, Corradini E, Porto G, Ryan J, Cornberg M. EASL Clinical Practice Guidelines on haemochromatosis. *Journal of Hepatology*. 2022;77(2):479-502. doi:10.1016/j.jhep.2022.03.033
26. Qiu Z, Chen X, Geng T, Wan Z, Lu Q, Li L, Zhu K, Zhang X, Liu Y, Lin X, Chen L, Shan Z, Liu L, Pan A, Liu G. Associations of Serum Carotenoids With Risk of Cardiovascular Mortality Among Individuals With Type 2 Diabetes: Results From NHANES. *Diabetes Care*. 2022;45(6):1453-1461.
doi:10.2337/dc21-2371
27. Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, Hall R, Harrower U, Hudson M, Langford A, Mackie A, Mitchell-Thain R, Sennett K, Sheron NC, Verne J, Walmsley

555 M, Yeoman A. Guidelines on the management of abnormal liver blood tests. *Gut*. 2018;67(1):6-
556 19. doi:10.1136/gutjnl-2017-314924

557 28. Ahlqvist E, Prasad RB, Groop L. Subtypes of Type 2 Diabetes Determined From Clinical
558 Parameters. *Diabetes*. 2020;69(10):2086-2093. doi:10.2337/dbi20-0001

559 29. Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De
560 Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Röther
561 J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I, ESC Scientific
562 Document Group, Widimsky P, Kolh P, Agewall S, Bueno H, Coca A, De Borst GJ, Delgado V, Dick
563 F, Erol C, Ferrini M, Kakkos S, Katus HA, Knuuti J, Lindholt J, Mattle H, Pieniazek P, Piepoli MF,
564 Scheinert D, Sievert H, Simpson I, Sulzenko J, Tamargo J, Tokgozoglu L, Torbicki A, Tsakountakis
565 N, Tuñón J, De Ceniga MV, Windecker S, Zamorano JL, Windecker S, Aboyans V, Agewall S,
566 Barbato E, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli
567 O, Hindricks G, Iung B, Juni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh T, Piepoli
568 MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Zelveian PH,
569 Haumer M, Isachkin D, De Backer T, Dilic M, Petrov I, Kirhmajer MV, Karetova D, Prescott E,
570 Soliman H, Paapstel A, Makinen K, Tosev S, Messas E, Pagava Z, Müller OJ, Naka KK, Járαι Z, et
571 al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in
572 collaboration with the European Society for Vascular Surgery (ESVS). *European Heart Journal*.
573 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095

574 30. R Core Team. R: A Language and Environment for Statistical Computing. Published online 2022.
575 <https://www.R-project.org/>

576 31. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative.
577 The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
578 statement: guidelines for reporting observational studies. *Lancet*. 2007;370(9596):1453-1457.
579 doi:10.1016/S0140-6736(07)61602-X

580 32. Allaire J. quarto: R Interface to “Quarto” Markdown Publishing System_. R package version 1.2.
581 Published online 2022. <https://CRAN.R-project.org/package=quarto>

582 33. Chang W, Cheng J, Allaire J, Sievert C, Schloerke B, Xie Y, Allen J, McPherson J, Dipert A, Borges
583 B. Shiny: Web Application Framework for R_. R package version 1.7.4.1. Published online 2023.
584 <https://CRAN.R-project.org/package=shiny>

585 34. Rossi E, McQuillan BM, Hung J, Thompson PL, Kuek C, Beilby JP. Serum Ferritin and C282Y
586 Mutation of the Hemochromatosis Gene as Predictors of Asymptomatic Carotid
587 Atherosclerosis in a Community Population. *Stroke*. 2000;31(12):3015-3020.
588 doi:10.1161/01.STR.31.12.3015

589 35. Zhou J, Zhao R, Wang D, Gao Q, Zhao D, Ouyang B, Hao L, Peng X. Sex-Specific Association
590 Between Iron Status and the Predicted 10-Year Risk for Atherosclerotic Cardiovascular Disease
591 in Hypertensive Patients. *Biol Trace Elem Res*. 2022;200(11):4594-4607. doi:10.1007/s12011-
592 021-03060-y

593 36. Ellervik C, Marott JL, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Total and cause-specific
594 mortality by moderately and markedly increased ferritin concentrations: general population
595 study and metaanalysis. *Clin Chem*. 2014;60(11):1419-1428.
596 doi:10.1373/clinchem.2014.229013

37. Kadoglou NPE, Biddulph JP, Rafnsson SB, Trivella M, Nihoyannopoulos P, Demakakos P. The association of ferritin with cardiovascular and all-cause mortality in community-dwellers: The English longitudinal study of ageing. *PLoS One*. 2017;12(6):e0178994. doi:10.1371/journal.pone.0178994
38. Amar Z, Talpur AS, Zafar S, Memon A, Nazary K, Esmati S, Hashim S, Maqsood H, Hafizyar F, Kumar B. Comparison of Iron Profile in Patients With and Without Coronary Heart Disease. *Cureus*. Published online June 12, 2021. doi:10.7759/cureus.15613
39. Vega De Céniga M, Bravo E, Izagirre M, Casco C, Estallo L, Esteban M, Barba A. Anaemia, Iron and Vitamin Deficits in Patients with Peripheral Arterial Disease. *European Journal of Vascular and Endovascular Surgery*. 2011;41(6):828-830. doi:10.1016/j.ejvs.2011.01.017
40. Otaki Y, Watanabe T, Takahashi H, Sugai T, Yokoyama M, Tamura H, Kato S, Nishiyama S, Arimoto T, Shishido T, Watanabe M. Impact of Iron Deficiency on Peripheral Artery Disease After Endovascular Therapy. *Circ Rep*. 2019;1(4):187-195. doi:10.1253/circrep.CR-18-0029
41. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart disease. *N Engl J Med*. 1994;330(16):1119-1124. doi:10.1056/NEJM199404213301604
42. Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I. Which is the best way for estimating transferrin saturation? *Renal Failure*. 2010;32(8):1022-1023. doi:10.3109/0886022X.2010.502609
43. Vinchi F, Sparla R, Passos ST, Sharma R, Vance SZ, Zreid HS, Juaidi H, Manwani D, Yazdanbakhsh K, Nandi V, Silva AMN, Agarvas AR, Fibach E, Belcher JD, Vercellotti GM, Ghoti H, Muckenthaler MU. Vasculo-toxic and pro-inflammatory action of unbound haemoglobin, haem and iron in transfusion-dependent patients with haemolytic anaemias. *Br J Haematol*. 2021;193(3):637-658. doi:10.1111/bjh.17361
44. Friedrich N, Milman N, Völzke H, Linneberg A, Jørgensen T. Is serum ferritin within the reference range a risk predictor of cardiovascular disease? A population-based, long-term study comprising 2874 subjects. *Br J Nutr*. 2009;102(4):594-600. doi:10.1017/S000711450922085X
45. Gillum RF, Sempos CT, Makuc DM, Looker AC, Chien CY, Ingram DD. Serum transferrin saturation, stroke incidence, and mortality in women and men. The NHANES I Epidemiologic Followup Study. National Health and Nutrition Examination Survey. *Am J Epidemiol*. 1996;144(1):59-68. doi:10.1093/oxfordjournals.aje.a008855
46. DePalma RG, Hayes VW, Cafferata HT, Mohammadpour HA, Chow BK, Zacharski LR, Hall MR. Cytokine signatures in atherosclerotic claudicants. *Journal of Surgical Research*. 2003;111(2):215-221. doi:10.1016/S0022-4804(03)00075-1
47. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hpcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. *Blood*. 2003;101(7):2461-2463. doi:10.1182/blood-2002-10-3235
48. Guida C, Altamura S, Klein FA, Galy B, Boutros M, Ulmer AJ, Hentze MW, Muckenthaler MU. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferrremia. *Blood*. 2015;125(14):2265-2275. doi:10.1182/blood-2014-08-595256

637 49. Marques O, Weiss G, Muckenthaler MU. The role of iron in chronic inflammatory diseases:
638 from mechanisms to treatment options in anemia of inflammation. *Blood*. 2022;140(19):2011-
639 2023. doi:10.1182/blood.2021013472

640 50. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D liang, Crooks DR, Sougrat R,
641 Morgenstern A, Galy B, Hentze MW, Lazaro FJ, Rouault TA, Meyron-Holtz EG. Serum ferritin is
642 derived primarily from macrophages through a nonclassical secretory pathway. *Blood*.
643 2010;116(9):1574-1584. doi:10.1182/blood-2009-11-253815

644 51. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on
645 clinical outcomes in peripheral arterial disease. *American Heart Journal*. 2011;162(5):949-
646 957.e1. doi:10.1016/j.ahj.2011.08.013

647 52. DePalma RG, Zacharski LR, Chow BK, Shamayeva G, Hayes VW. Reduction of iron stores and
648 clinical outcomes in peripheral arterial disease: outcome comparisons in smokers and non-
649 smokers. *Vascular*. 2013;21(4):233-241. doi:10.1177/1708538113478776

650

Legends

Table 1. Demographics of HEIST-DiC participants

The demographics of the HEIST-DiC participants classified by sex and the presence of PAD are shown in Table 1. For continuous variables, the summary data are shown as Mean±Standard Deviation and for categorical variables as N (%). P-values as calculated by the Wilcoxon rank sum test or Fisher's exact test and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, HbA1c: Glycated hemoglobin, ICAM1: Intercellular Adhesion Molecule 1, VCAM1: Vascular Cell Adhesion Molecule 1, hsCRP: High sensitivity C-reactive protein, IL6: Interleukin 6, hsTNT: High sensitivity Troponin T, proBNP: N-Terminal B-type Natriuretic Peptide, eGFR: Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation

Table 2. Demographics of NHANES 1999-2004 participants

The demographics of the NHANES 1999-2004 participants classified by sex and the presence of PAD are shown in Table 2. The N of participants shown are unweighted numbers. For continuous variables, the summary data are shown as Median (Interquartile Range), and for categorical variables as N (%)- survey weights were included in calculating the summary data. P-values as calculated by the Wilcoxon rank sum test or Fisher's exact test and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, HbA1c: Glycated hemoglobin, CRP: High sensitivity C-reactive protein, eGFR: Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation, TIBC: Total Iron Binding Capacity, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, FIB4: Fibrosis-4 index

Figure 1. Odds Ratio plot of iron parameters with PAD: HEIST-DiC participants

The plot shows a compilation of the OR (odds ratio) and 95% CI (95% Confidence Interval) derived from the logistic regression analysis (sex-stratified) of each of the iron parameters with PAD.

Model 1: represents the univariate analysis. Model 2: adjusted for the presence of diabetes and hypertension. Model 3: adjusted for the presence of diabetes and hypertension, High sensitivity C-reactive protein, Urine Albumin-Creatinine Ratio, and Low-density Lipoprotein.

Figure 2. The coefficient plot of iron parameters with ICAM-1: HEIST-DiC participants

The plot shows a compilation of the estimate and 95% CI (95% Confidence Interval) derived from the linear regression analysis (sex-stratified) of each of the iron parameters with PAD.

Model 1: represents the univariate analysis. Model 2: adjusted for the presence of diabetes and hypertension. Model 3: adjusted for the presence of diabetes and hypertension, High sensitivity C-reactive protein, Urine Albumin-Creatinine Ratio, and Low-density Lipoprotein.

Figure 3. The coefficient plot of iron parameters with VCAM-1: HEIST-DiC participants

The plot shows a compilation of the estimate and 95% CI (95% Confidence Interval) derived from the linear regression analysis (sex-stratified) of each of the iron parameters with PAD.

Model 1: represents the univariate analysis. Model 2: adjusted for the presence of diabetes and hypertension. Model 3: adjusted for the presence of diabetes and hypertension, High sensitivity C-reactive protein, Urine Albumin-Creatinine Ratio, and Low-density Lipoprotein.

Figure 4. The Odds Ratio plot of iron parameters with PAD: NHANES 1999-2004 participants

The plot shows a compilation of the OR (odds ratio) and 95% CI (95% Confidence Interval) derived from the logistic regression analysis (sex-stratified) of each of the iron parameters with PAD.

Model 1: represents the univariate analysis. Model 2: adjusted for age, ethnicity, BMI and smoking. Model 3: adjusted for age, ethnicity, BMI, smoking, the presence of diabetes and

hypertension, FIB4 score, Urine Albumin-Creatinine Ratio, and C-reactive protein. Model 4: adjusted for age, ethnicity, BMI, smoking, the presence of diabetes and hypertension, FIB4 score, Urine Albumin-Creatinine Ratio, C-reactive protein, LDL, antihyperlipidemic and antiplatelet medications, and HOMA2-IR.

Supplementary files

Supplementary Table 1. Model 4 Regression Summary NHANES 1999-2004.

The table shows the regression results of the multivariate Model 4 analysis of iron biomarkers with PAD. The Odds ratio, 95% confidence interval, and p-value are shown in the table. The significant associations are highlighted in bold.

Supplementary Table 2. Data fields and variables from NHANES 1999-2004.

The table shows the variables and the corresponding codes used for accessing data from the NHANES. The hyperlinks to the procedure manuals and datafiles are also provided in the table.

Supplementary Figure 1. The Odds Ratio plot of iron parameters with PAD: Sensitivity analysis of NHANES 1900-2004 participants

Table 1. Baseline characteristics of HEIST-DiC participants

	Males (N=192)				Females (N=165)			
Variable	N	No PAD N = 175	PAD N = 17	P-value	N	No PAD N = 159	PAD N = 6¹	P-value
Age	192	60 (11)	70 (8)	<0.001	165	59 (11)	68 (7)	0.025
BMI	192	29.8 (5.1)	30.8 (6.0)	0.6	165	29.6 (6.3)	34.6 (5.1)	0.036
Hypertension	192			0.09^F				0.028^F
No	70	67 (38%)	3 (18%)		82	82 (52%)	0 (0%)	
Yes	122	108 (62%)	14 (82%)		165	77 (48%)	6 (100%)	
Diabetes	192			0.067 ^F	165			0.3 ^F
No diabetes	37	37 (21%)	0 (0%)		67	66 (42%)	1 (17%)	
Prediabetes	19	17 (9.7%)	2 (12%)		18	18 (11%)	0 (0%)	
Diabetes	136	121 (69%)	15 (88%)		80	75 (47%)	5 (83%)	
Dietary management (=Yes)	192	19 (11%)	3 (18%)	0.4 ^F	165	9 (5.7%)	1 (17%)	0.3 ^F
Oral antidiabetic medications (=Yes)	192	60 (34%)	7 (41%)	0.6 ^F	165	41 (26%)	2 (33%)	0.7 ^F
Statins (=Yes)	192	57 (33%)	6 (35%)	0.8 ^F	165	27 (17%)	2 (33%)	0.3 ^F
Fasting blood glucose (mg/dL)	192	135 (47)	175 (59)	0.002	165	121 (40)	157 (50)	0.067
HbA1c (g/dL)	192	6.78 (3.10)	7.40 (1.43)	0.014	165	6.25 (1.19)	7.13 (1.13)	0.056

Insulin	192	30 (17%)	5 (29%)	0.2	165	22 (14%)	2 (33%)	0.2
Parameters of vascular function								
Ankle-brachial index (Right)	191	1.11 (0.08)	0.84 (0.11)	<0.001	164	1.09 (0.08)	0.81 (0.06)	<0.001
Ankle-brachial index (Left)	191	1.12 (0.08)	0.90 (0.09)	<0.001	161	1.09 (0.08)	0.93 (0.08)	<0.001
Carotid intima-media thickness (mm)	176	0.63 (0.16)	0.71 (0.13)	0.025	161	0.59 (0.13)	0.83 (0.17)	0.002
Carotid-femoral Pulse Wave Velocity	185	8.79 (1.79)	10.43 (1.94)	0.004	163	8.43 (1.86)	11.80 (1.24)	0.002
ICAM1	162	287 (104)	363 (93)	0.008	134	308 (111)	269 (82)	0.6
VCAM1	162	869 (247)	1,035 (282)	0.017	134	828 (211)	743 (240)	0.8
Other laboratory parameters								
Triglycerides (mg/dL)	192	171 (166)	204 (100)	0.011	165	140 (93)	384 (567)	0.092
Cholesterol (mg/dL)	192	190 (47)	197 (59)	0.8	165	206 (42)	194 (41)	0.5
HDL (mg/dL)	192	49 (13)	43 (8)	0.067	165	61 (18)	55 (29)	0.3
LDL (mg/dL)	179	111 (42)	108 (37)	0.9	158	118 (35)	93 (23)	0.088
Hemoglobin (g/dL)	192	14.85 (1.06)	14.41 (1.26)	0.14	165	13.59 (0.93)	13.23 (1.30)	0.5
Mean Corpuscular	192	88.8 (4.6)	91.2 (5.7)	0.2	165	88.3 (4.2)	87.7 (5.0)	0.7

Volume (fL)								
hsCRP	184	2.11 (3.10)	3.68 (5.82)	0.3	159	3.5 (4.2)	7.9 (7.4)	0.083
IL6	150	3.16 (1.85)	4.44 (2.98)	0.010	128	3.42 (2.02)	4.50 (2.47)	0.3
hsTNT	174	10.8 (9.3)	13.7 (6.8)	0.033	147	7.1 (5.2)	11.6 (10.1)	0.2
proBNP	174	136 (365)	155 (149)	0.052	147	113 (197)	229 (149)	0.008
eGFR (ml/min/1.73m ²)	192	91 (17)	76 (17)	0.002	165	91 (16)	67 (25)	0.016
Urinary Albumin Creatinine Ratio (mg/g)	188	81 (454)	130 (229)	0.001	164	29 (104)	72 (94)	0.012
Iron-related parameters								
Iron	192	17.8 (5.9)	18.1 (7.5)	0.7	165	16.9 (5.8)	18.0 (5.9)	0.6
Ferritin	192	189 (157)	232 (134)	0.10	165	99 (81)	198 (146)	0.031
Transferrin	189	2.41 (0.31)	2.41 (0.37)	0.6	161	2.47 (0.38)	2.57 (0.38)	0.6
TSAT (%)	189	27 (9)	23 (6)	0.2	159	25 (9)	22 (10)	0.5

Table 1. Demographics of HEIST-DiC participants

The demographics of the HEIST-DiC participants classified by sex and the presence of PAD are shown in Table 1. For continuous variables, the summary data are shown as Mean±Standard Deviation and for categorical variables as N (%). P-values as calculated by the Wilcoxon rank sum test or Fisher's exact test^F and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, HbA1c: Glycated hemoglobin, ICAM1: Intercellular Adhesion Molecule 1, VCAM1: Vascular Cell Adhesion Molecule 1, hsCRP: High sensitivity C-reactive protein, IL6: Interleukin 6, hsTNT: High sensitivity Troponin T, proBNP: N-Terminal B-type Natriuretic Peptide, eGFR: Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation

Nonsmoker	1,488 (37)	1,419 (33.9)	69 (1.7)	<0.001 ^F	1,899 (57)	1,729 (54.4)	170 (5.4)	0.2 ^F
Former smoker	1,776 (41)	1,602 (38.3)	174 (4.2)		792 (26)	692 (21.8)	100 (3.1)	
Current smoker	919 (22)	821 (19.6)	98 (2.3)		487 (17)	431 (13.6)	56 (1.8)	
Alcohol drinker (coded)								
No	282 (34)	263 (33.2)	19 (2.4)	0.6 ^F	723 (43)	632 (41.8)	91 (6.01)	>0.9 ^F
Yes	511 (66)	470 (59.3)	41 (5.2)		790 (57)	690 (45.6)	100 (6.6)	
Physical activity (coded)								
Sedentary	1,922 (42)	1,758 (42.9)	164 (4)	0.8 ^F	1,550 (43)	1,379 (45.2)	171 (5.6)	0.087 ^F
Low to Moderate	1,313 (38)	1,220 (29.8)	93 (2.3)		938 (37)	851 (27.9)	87 (2.9)	
Vigorous	863 (20)	793 (19.4)	70 (1.71)		564 (20)	524 (17.2)	40 (1.3)	
Antihyperlipidemic medications (coded)								
No	3,118 (82)	2,866 (76.4)	252 (6.7)	<0.001 ^F	2,519 (87)	2,277 (77.9)	242 (8.3)	<0.001 ^F
Yes	634 (18)	560 (14.9)	74 (1.97)		405 (13)	337 (11.5)	68 (2.3)	
Antiplatelet medications (coded)								
No	3,665 (98)	3,359 (89.5)	306 (8.2)	<0.001 ^F	2,861 (98)	2,563 (68.3)	298 (7.9)	0.006 ^F
Yes	87 (1.6)	67 (1.8)	20 (0.5)		63 (1.7)	51 (1.4)	12 (0.3)	
Ankle-brachial Index (Left)	1.16 (1.10, 1.22)	1.17 (1.11, 1.22)	0.87 (0.79, 0.98)	<0.001	1.11 (1.04, 1.19)	1.12 (1.06, 1.19)	0.88 (0.78, 0.96)	<0.001
Ankle-brachial Index (Right)	1.16 (1.10, 1.22)	1.16 (1.11, 1.22)	0.87 (0.75, 0.96)	<0.001	1.10 (1.03, 1.18)	1.11 (1.05, 1.19)	0.86 (0.77, 0.90)	<0.001

Albumin (g/L)	44.0 (42.0, 46.0)	44.0 (42.0, 46.0)	43.0 (41.0, 45.0)	<0.001	43.0 (41.0, 44.4)	43.0 (41.0, 45.0)	42.0 (39.0, 44.0)	0.003
AST (U/L)	26 (21, 33)	26 (21, 34)	22 (18, 27)	<0.001	19 (16, 25)	19 (16, 25)	20 (16, 25)	0.9
ALT (U/L)	24 (21, 29)	24 (21, 29)	23 (20, 29)	0.2	21 (18, 25)	21 (18, 25)	22 (19, 26)	0.087
Blood urea nitrogen (mmol/L)	5.36 (4.28, 6.10)	5.00 (4.28, 6.10)	6.07 (4.64, 7.14)	<0.001	4.60 (3.57, 5.71)	4.60 (3.57, 5.71)	5.00 (3.90, 7.14)	0.010
Creatinine (μmol/L)	88 (71, 97)	88 (71, 97)	88 (80, 115)	0.002	62 (62, 80)	62 (53, 71)	80 (62, 88)	<0.001
Total Cholesterol (mmol/L)	5.22 (4.55, 5.89)	5.22 (4.55, 5.90)	4.86 (4.04, 5.58)	0.003	5.33 (4.71, 6.03)	5.33 (4.71, 6.03)	5.38 (4.81, 5.95)	0.7
Triacylglycerols (mmol/L)	1.49 (1.01, 2.24)	1.49 (1.01, 2.24)	1.47 (0.97, 2.37)	0.8	1.22 (0.81, 1.82)	1.20 (0.80, 1.78)	1.59 (1.09, 2.45)	<0.001
LDL (mmol/L)	3.16 (2.61, 3.75)	3.18 (2.61, 3.78)	2.85 (2.17, 3.41)	0.025	3.13 (2.59, 3.72)	3.13 (2.59, 3.72)	3.05 (2.50, 3.62)	0.8
HDL (mmol/L)	1.14 (0.98, 1.39)	1.14 (0.98, 1.40)	1.16 (0.96, 1.34)	0.6	1.45 (1.19, 1.73)	1.45 (1.22, 1.73)	1.32 (1.11, 1.55)	0.001
Fasting plasma glucose (mmol/L)	5.62 (5.24, 6.21)	5.61 (5.25, 6.16)	5.89 (5.18, 6.73)	0.5	5.29 (4.97, 5.79)	5.28 (4.95, 5.74)	5.81 (5.36, 6.93)	<0.001
Insulin (pmol/L)	57 (38, 91)	57 (38, 90)	70 (41, 108)	0.14	46 (32, 79)	46 (31, 74)	106 (47, 190)	<0.001
CRP (mg/dL)	0.17 (0.08, 0.35)	0.17 (0.08, 0.35)	0.26 (0.17, 0.43)	<0.001	0.25 (0.10, 0.58)	0.25 (0.10, 0.57)	0.33 (0.15, 0.90)	0.009
Hemoglobin (g/dL)	15.20 (14.60, 16.00)	15.20 (14.70, 16.00)	14.90 (14.10, 15.60)	<0.001	13.80 (13.10, 14.50)	13.90 (13.10, 14.50)	13.80 (12.90, 14.80)	>0.9


FIB4 Score	1.15 (0.91, 1.51)	1.14 (0.90, 1.50)	1.35 (1.10, 1.67)	<0.001	0.87 (0.64, 1.17)	0.84 (0.63, 1.15)	1.11 (0.83, 1.44)	<0.001
Albumin-creatinine ratio (µg/mg)	0.60 (0.41, 1.06)	0.58 (0.40, 1.00)	1.13 (0.65, 2.78)	<0.001	0.80 (0.54, 1.51)	0.77 (0.53, 1.40)	1.30 (0.70, 2.59)	<0.001
Iron (µg/dL)	91 (72, 115)	92 (73, 115)	80 (64, 108)	<0.001	78 (60, 99)	79 (60, 99)	75 (57, 96)	0.2
Ferritin (µg/dL)	146 (96, 259)	146 (97, 258)	127 (81, 262)	0.5	64 (32, 109)	62 (31, 106)	87 (56, 252)	<0.001
TSAT (%)	26 (21, 33)	26 (21, 33)	24 (17, 30)	0.021	22 (16, 29)	22 (16, 29)	20 (16, 30)	0.5
TIBC (µmol/L)	63 (57, 70)	63 (57, 70)	65 (58, 72)	0.5	63 (58, 71)	64 (58, 71)	60 (54, 68)	0.001

Table 2. Demographics of NHANES 1999-2004 participants


The demographics of the NHANES 1999-2004 participants classified by sex and the presence of PAD are shown in Table 2. The N of participants shown are unweighted numbers. For continuous variables, the summary data are shown as Median (Interquartile Range), and for categorical variables as N (%)-survey weights were included in calculating the summary data. P-values as calculated by the Wilcoxon rank sum test or Fisher's exact test^F and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, HbA1c: Glycated hemoglobin, CRP: High sensitivity C-reactive protein, eGFR: Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation, TIBC: Total Iron Binding Capacity, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, FIB4 Score: Fibrosis-4 index Score


Serum iron indices vs PAD: HEIST–DiC



Serum iron indices vs ICAM1: HEIST-DiC



Serum iron indices vs VCAM1: HEIST–DiC



Iron parameters vs PAD: NHANES

